Clinical Trial Update: Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for lenalidomide in combination with sunitinib in renal cell carcinoma shows terminated status with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Sunitinib (sunitinib)

Snippet

Sponsor: Celgene | Conditions: Renal Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2014-12-29